Eli Lilly and Co (NYSE:LLY) on Wednesday shared topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials of oral orforglipron for reducing blood sugar levels.

LLY is gathering positive momentum. See what is happening here.

ACHIEVE-2, the second head-to-head trial, evaluated orforglipron versus AstraZeneca Plc’s (NASDAQ:AZN) Farxiga (dapagliflozin) in adults with type 2 diabetes inadequately controlled on commonly used metformin.

Separately, ACHIEVE-5 assessed orforglipron versus placebo in adults with type 2 diabetes and inadequate glycemic control with titrated insulin glargine, with or without metformin and/or SGLT-2 inhibitors.

Data

In both trials, orforglipron (3 mg, 12 mg, 36 mg) met the primary and all ...